Comparison of Different Chronic Maintenance Antithrombotic Strategies in Patients with Coronary Artery Disease: A Systematic Review and Network Meta-Analysis

Table 1

Baseline characteristics of the included studies.

Research/year	Maintenance regimen	Age, yr.	Male, (%)	ACS, (%)	Hypertension, (%)	Diabetes, (%)	Dyslipidemia, (%)	Chronic kidney disease, (%)	Previous MI, (%)
HOST-EXAM trial/2021	Aspirin ()	63·4 (10·7)	2039 (74·7%)	1957 (71.7%)	1674 (61·4%)	935 (34·3%)	1883 (69·0%)	337 (12·4%)	435 (15·9%)
	Clopidogrel ()	63·5 (10·7)	2015 (74·4%)	1964 (72.5%)	1664 (61·4%)	925 (34·1%)	1884 (69·5%)	356 (13·1%)	437 (16·1%)
CAPRIE/1996	Aspirin ()	58·3 (11·3)	81%	34%	38%	15%	42%	ND	ND
	Clopidogrel ()	58·6 (11·4)	81%	34%	39%	14%	41%	ND	ND
THEMIS-PCI/2019	Aspirin ()	66·0 (61·0–72·0)	3880 (69.8)	ND	5136 (91·8)	5596 (100%)	4967 (88·8)	ND	ND
	Ticagrelor ()	66·0 (61·0–72·0)	3838 (69.1)	ND	5127 (92·2)	5558 (100%)	4922 (88·6)	ND	ND
GLOBAL LEADERS landmark-analysis/2022	Aspirin ()		4519 (77.7)	2585 (44.5%)	72.8 (4,214/5,792)	24.1 (1,402/5,810)	70.4 (3,970/5,639)	ND	22.9 (1,326/5,801)
	Ticagrelor ()		4135 (77.9)	2566 (48.3%)	73.4 (3,885/5,290)	24.3 (1,287/5,303)	69.6 (3,561/5,119)	ND	21.8 (1,153/5,295)
ARCTIC-Interruption/2014	Aspirin ()	64 (57–73)	503 (81%)	ND	388 (62%)	222 (36%)	426 (68%)	ND	186 (30%)
	Aspirin plus clopidogrel ()	64 (57–73)	508 (80%)	ND	376 (59%)	198 (31%)	428 (67%)	ND	197 (31%)
DAPT/2014	Aspirin ()		3657 (74%)	2103 (42.6%)	3649/4934 (74.0)	1481/4927 (30.1)	ND	ND	1026/4870 (21.1)
	Aspirin plus clopidogrel ()		3778 (75.3%)	2148 (42.8%)	3796/5006 (75.8)	1556/5006 (31.1)	ND	ND	1092/4953 (22.0)
DES-LATE/2013	Aspirin ()		1749 (69.6%)	1551 (61.7%)	1423 (56.6%)	709 (28.2%)	ND	ND	92 (3.7%)
	Aspirin plus clopidogrel ()		1749 (69.1%)	1512 (59.7%)	1479 (58.4%)	709 (28.0%)	ND	ND	103 (4.1%)
OPTIDUAL/2016	Aspirin ()		547 (79.3%)	262 (38.0%)	417 (60.4)	222 (32.2)	ND	ND	122 (17.7)
	Aspirin plus clopidogrel ()		568 (81.7%)	239 (34.4%)	396 (57.0)	213 (30.6)	ND	ND	119 (17.1)
PEGASUS-TIMI 54/2015	Aspirin ()		5350 (75.7%)	6652/7057 (94.3%)	5484 (77.6)	2257 (31.9)	5451 (77.1)	1649/6985 (23.6)	7067 (100%)
	Aspirin plus ticagrelor 60 mg ()		5384 (76.4%)	6599/7035 (93.8%)	5461 (77.5)	2308 (32.8)	5380 (76.4)	1547/6955 (22.2)	7045 (100%)
	Aspirin plus ticagrelor 90 mg ()		5368 (76.1%)	6661/7043 (94.6%)	5462 (77.5)	2241 (31.8)	5410 (76.7)	1653/6958 (23.8)	7050 (100%)
COMPASS/2017	Aspirin ()	69 (65–73)	6615 (80%)	ND	6280 (76%)	3040 (37%)	ND	ND	5721 (69%)
	Aspirin plus low-dose rivaroxaban ()	69 (65–73)	6577 (79%)	ND	6218 (75%)	3043 (37%)	ND	ND	5654 (68%)

BMI: body mass index; PCI: percutaneous coronary intervention; RCT: randomized controlled trial; STEMI: ST-segment elevation myocardial infarction; ACS: acute coronary syndrome; DAPT: dual antiplatelet therapy; MI: myocardial infarction; ST: stent thrombosis; MACE: major adverse cardiac event; NACE: net adverse clinical event.